

Proteintech's Cancer Immunotherapy Early-Career Researcher Meeting

Thursday 28th April 2022

Time: CT/BST	Title	Speaker
9.00-9.10/ 15.05-15.10	Event and Chair Introduction	Dr Lydia Lee Clinical Research Fellow, University College London, UK
9.10-9.40/ 15.10-15.40	Keynote: Manipulating inflammation to raise cancer immunogenicity and the response to immunotherapy	Dr Santiago Zelenay Group Leader, Cancer Research UK, Manchester
9.40-10.00/ 15.40-16.00	T cell-derived interferon (IFN) γ in combination with arachidonic acid (AA) induces immunogenic tumor ferroptosis, serving as a mode of action for CD8+ T cells (CYL)-mediated tumor killing	Dr Peng Liao Postdoctoral Research Fellow, University of Michigan, US
10.00-10.20/ 16.00-16.20	Loss of Nr4a1 is associated with higher expression of immune checkpoint components and reduced T cell-mediated lymphoma cell killing in aggressive lymphoma	Katrin Pansy PhD Student, Medical University of Graz, Austria
10.20-10.40/ 16.20-16.40	Listeria-based vaccine targeting interferon-stimulated gene 15 for renal cell carcinoma	My Nguyen PhD Student, Texas Tech University Health Science, US
10.40-11.00/ 16.40-17.00	Targeting the alpha-ketoglutarate dehydrogenase complex reduces the immunosuppressive function of CD11b +Gr1+ myeloid cells and inhibits ovarian cancer growth	Dr Mary Priyankar Udumula Postdoctoral Research Fellow, Henry Ford Health System, Detroit, US
11.00-11.30/ 17.00-17.30	Keynote: Biological Cancer Immunotherapies: Challenges at the Bench and at the Bedside	Dr Mike Chapman MRC Investigator, University of Cambridge, UK